253 related articles for article (PubMed ID: 34019229)
21. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.
Lebwohl M; Soliman AM; Yang H; Wang J; Freimark J; Puig L
J Dermatolog Treat; 2022 Jun; 33(4):2094-2101. PubMed ID: 33899655
[TBL] [Abstract][Full Text] [Related]
22. Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study.
Pinter A; Soliman AM; Pivneva I; Ghanbariamin R; Yang M; Truong B; Puig L; Lebwohl M
Dermatol Ther (Heidelb); 2024 May; 14(5):1259-1271. PubMed ID: 38727996
[TBL] [Abstract][Full Text] [Related]
23. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
[TBL] [Abstract][Full Text] [Related]
24. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
Mattei PL; Corey KC; Kimball AB
J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Papp KA; Lebwohl MG; Puig L; Ohtsuki M; Beissert S; Zeng J; Rubant S; Sinvhal R; Zhao Y; Soliman AM; Alperovich G; Leonardi C
Br J Dermatol; 2021 Dec; 185(6):1135-1145. PubMed ID: 34157132
[TBL] [Abstract][Full Text] [Related]
26. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
[TBL] [Abstract][Full Text] [Related]
27. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
28. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Strober B; Bachelez H; Crowley J; Elewski BE; Gooderham M; Menter A; Strohal R; Chen MM; Wu T; Zhan T; Photowala H; Armstrong A
J Eur Acad Dermatol Venereol; 2024 May; 38(5):864-872. PubMed ID: 38179809
[TBL] [Abstract][Full Text] [Related]
30. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
32. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation.
Odnopozova L; Edin A; Sukharev A; Wu T; Aydin K; Kelly M; Khotko A
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2063-2075. PubMed ID: 35917057
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
[TBL] [Abstract][Full Text] [Related]
34. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis.
Yu N; Peng C; Zhou J; Gu J; Xu J; Li X; Bi X; Deng H; Li X; Ding Y; Shi Y
Br J Dermatol; 2023 Sep; 189(4):437-446. PubMed ID: 37310289
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.
Papp KA; de Vente S; Zeng J; Flack M; Padilla B; Tyring SK
Dermatol Ther (Heidelb); 2021 Apr; 11(2):487-497. PubMed ID: 33512666
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
[TBL] [Abstract][Full Text] [Related]
37. Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D; Soliman AM; Eyerich K; Pinter A; Sebastian M; Unnebrink K; Rubant S; Williams DA; Weisenseel P
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1686-1691. PubMed ID: 33428281
[TBL] [Abstract][Full Text] [Related]
38. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Griffiths CE; Vender R; Sofen H; Kircik L; Tan H; Rottinghaus ST; Bachinsky M; Mallbris L; Mamolo C
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):323-332. PubMed ID: 27600367
[TBL] [Abstract][Full Text] [Related]
39. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
[TBL] [Abstract][Full Text] [Related]
40. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.
Gargiulo L; Ibba L; Pavia G; Vignoli CA; Piscazzi F; Valenti M; Sanna F; Perugini C; Avagliano J; Costanzo A; Narcisi A
Dermatol Ther (Heidelb); 2022 Oct; 12(10):2309-2324. PubMed ID: 36063283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
